IceCure Medical Reports Over 30% Q1 U.S. ProSense® Revenue Growth; Cost-Saving Study Wins Award

summarizeSummary

IceCure Medical announced preliminary Q1 2026 U.S. revenue for its ProSense® system increased over 30% year-over-year, supported by an award-winning study highlighting significant cost savings compared to traditional surgery.

check_boxKey Events

• Strong U.S. Revenue Growth

  IceCure Medical expects to report preliminary, unaudited U.S. revenue for ProSense® systems and cryoprobes increased by over 30% in Q1 2026 compared to Q1 2025.

• Post-FDA Clearance Momentum

  The revenue growth is attributed to the adoption of ProSense® following its FDA clearance for low-risk breast cancer in women aged 70 and above in October 2025.

• Award-Winning Cost-Effectiveness Study

  A study featuring ProSense® cryoablation won an SBI 2026 Abstract Award, demonstrating a potential 50%+ reduction in total treatment costs compared to breast-conserving surgery.

• Expanding Market Presence

  The company is expanding its installed base of ProSense® systems in the U.S., including placements at leading academic hospitals, and expects new system sales in Q2 2026.

auto_awesomeAnalysis

IceCure Medical reported preliminary, unaudited U.S. revenue growth of over 30% for its ProSense® systems and cryoprobes in the first quarter of 2026 compared to the prior year. This significant operational improvement follows the FDA clearance of ProSense® for low-risk breast cancer in October 2025 and indicates accelerating commercial momentum. The positive news is further bolstered by an award-winning study demonstrating ProSense® cryoablation can reduce treatment costs by more than 50% compared to breast-conserving surgery. This strong performance and clinical validation are particularly important for IceCure Medical, which recently filed an F-3/A shelf registration to address a 'going concern' warning, suggesting these positive developments could help alleviate financial pressures and improve investor sentiment.